Changing and saving lives one fresh breath at a time.
Plasm® Pharmaceutical was established with the expressed purpose of funding and pursuing clinical trials in Canada and the USA for its promising drug treatment for respiratory diseases. The more immediate interest and focus will be on the urgently needed treatment of COVID-19 patients in distress.
CavaltinibTM, the subject drug, displays novel pharmacology and has been shown in recent medical discoveries by Biologic Pharmamedical Research, a parent biotech corporation, to be a fit as a drug candidate for COVID-19 patient treatment. This candidate drug has been run through a research program that was designed to study key drug targets involved in the regulation of immune system and inflammatory activity.
Research has already shown CavaltinibTM irrefutably inhibits, the NF-kappa-B Signalling Pathway through mechanisms discovered by, Biologic Pharmamedical’s principle scientist, Franco Cavaleri. A discovery by a Canadian scientist in a Canadian drug research program. As a consequence of its down-regulation the inhibition of several downstream cytokines ensues; cytokines central to the ‘cytokine storm’ phenomenon characteristic of the COVID-19 pathology (IL-1, IL-2, IL-3, IL-6 and several other cytokines).
Plasm's mission is to demonstrate this activity in the context of COVID-19 patients in a clinical setting and further assert that this pharmacology can play a significant role in these patients to circumvent morbidity and mortality. The objective is to expand the indications to other respiratory diseases using this mechanism and path to drug status.